Mural Oncology (NASDAQ:MURA) Lowered to Outperform Rating by Raymond James

Mural Oncology (NASDAQ:MURA) was downgraded by investment analysts at Raymond James from a “strong-buy” rating to an “outperform” rating in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. They currently have a $18.00 price objective on the stock.

MURA has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Mural Oncology in a research report on Wednesday, March 12th. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a report on Tuesday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Mural Oncology Trading Down 60.1 %

Shares of NASDAQ MURA traded down $2.30 during mid-day trading on Tuesday, reaching $1.53. The company had a trading volume of 2,861,627 shares, compared to its average volume of 157,436. Mural Oncology has a 52 week low of $2.87 and a 52 week high of $5.12. The business’s 50-day moving average is $3.91 and its 200-day moving average is $3.63. The stock has a market cap of $26.36 million, a price-to-earnings ratio of -0.17 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last issued its earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period last year, the firm earned ($3.57) EPS. As a group, equities research analysts forecast that Mural Oncology will post -7.54 earnings per share for the current year.

Institutional Investors Weigh In On Mural Oncology

A number of large investors have recently modified their holdings of MURA. Commerce Bank acquired a new stake in Mural Oncology in the 3rd quarter worth approximately $39,000. FMR LLC raised its holdings in shares of Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after buying an additional 11,423 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Mural Oncology in the third quarter worth $340,000. Geode Capital Management LLC lifted its stake in shares of Mural Oncology by 2.6% during the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock worth $595,000 after buying an additional 4,731 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Mural Oncology during the fourth quarter valued at $181,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.